Tarceva and Capecitabine for Pancreatic Cancer
This phase II trial is designed to investigate the effectiveness of Tarceva (OSI-774) combined with capecitabine in treating patients with metastatic pancreatic cancer.
Pancreatic Cancer|Neoplasm Metastasis
DRUG: Capecitabine|DRUG: OSI-774
To assess the response rate associated with capecitabine and OSI-774 in patients with advanced pancreatic cancer
To assess the side effects of capecitabine and OSI-774 in patients with advanced pancreatic cancer, 2 years|to estimate the time to progression and overall survival of patients with advanced pancreatic cancer treated with capecitabine and OSI-774
Patients will be treated once daily with Tarceva, twice daily with capecitabine for 14 consecutive days, followed by 7 days off of capecitabine (a cycle is 21 days). At week 1 of each cycle a physical exam and blood work will be performed. Reassessment of tumor size will be conducted at 6 weeks (2 cycles), 12 weeks (4 cycles) and then every 9 weeks thereafter. Patients will remain on treatment until one of the following occur: disease progression, illness that prevents further treatment or unacceptable adverse events.